BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkilä P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008;40:844-53. [PMID: 18511948 DOI: 10.1038/ng.155] [Cited by in Crossref: 151] [Cited by in F6Publishing: 141] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Bégin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012;107:800-7. [PMID: 22850554 DOI: 10.1038/bjc.2012.338] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 11.1] [Reference Citation Analysis]
2 Jamshidi M, Schmidt MK, Dörk T, Garcia-Closas M, Heikkinen T, Cornelissen S, van den Broek AJ, Schürmann P, Meyer A, Park-Simon TW, Figueroa J, Sherman M, Lissowska J, Keong GT, Irwanto A, Laakso M, Hautaniemi S, Aittomäki K, Blomqvist C, Liu J, Nevanlinna H. Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. Int J Cancer 2013;132:2044-55. [PMID: 23034890 DOI: 10.1002/ijc.27884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Geng R, Chen Z, Zhao X, Qiu L, Liu X, Liu R, Guo W, He G, Li J, Zhu X. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy. PLoS One 2014;9:e116027. [PMID: 25545243 DOI: 10.1371/journal.pone.0116027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
4 Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. [PMID: 20520800 DOI: 10.1371/journal.pmed.1000279] [Cited by in Crossref: 550] [Cited by in F6Publishing: 525] [Article Influence: 45.8] [Reference Citation Analysis]
5 Arakawa N, Okubo A, Yasuhira S, Takahashi K, Amano H, Akasaka T, Masuda T, Shibazaki M, Maesawa C. Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of β-lapachone in melanoma cell lines. Oncol Lett 2018;15:2393-400. [PMID: 29434949 DOI: 10.3892/ol.2017.7618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Pelttari LM, Kinnunen L, Kiiski JI, Khan S, Blomqvist C, Aittomäki K, Nevanlinna H. Screening of HELQ in breast and ovarian cancer families. Familial Cancer 2016;15:19-23. [DOI: 10.1007/s10689-015-9838-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Takakuwa O, Oguri T, Ozasa H, Uemura T, Kunii E, Kasai D, Miyazaki M, Maeno K, Sato S. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin. J Thorac Oncol 2011;6:1826-32. [PMID: 21964527 DOI: 10.1097/JTO.0b013e318229137d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
8 Olivera G, Sendra L, Herrero MJ, Puig C, Aliño SF. Colorectal cancer: pharmacogenetics support for the correct drug prescription. Pharmacogenomics 2019;20:741-63. [PMID: 31368847 DOI: 10.2217/pgs-2019-0041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Dai X, Guo W, Zhan C, Liu X, Bai Z, Yang Y. WDR5 Expression Is Prognostic of Breast Cancer Outcome. PLoS One 2015;10:e0124964. [PMID: 26355959 DOI: 10.1371/journal.pone.0124964] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
10 Hübner RH, Schwartz JD, De Bishnu P, Ferris B, Omberg L, Mezey JG, Hackett NR, Crystal RG. Coordinate control of expression of Nrf2-modulated genes in the human small airway epithelium is highly responsive to cigarette smoking. Mol Med 2009;15:203-19. [PMID: 19593404 DOI: 10.2119/molmed.2008.00130] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
11 Song A, Wu G, Hang H, Wang L. Rosiglitazone pretreatment influences thrombin-induced anti-oxidative action via activating NQO1and γ-GCS in rat microglial cells. Neurol Res 2018;40:139-45. [PMID: 29262765 DOI: 10.1080/01616412.2017.1417686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Blevins S, Siegel PB, Blodgett DJ, Ehrich M, Lewis RM. Liver enzymes in White Leghorns selected for the sheep red blood cell immune response. Poult Sci 2012;91:322-6. [PMID: 22252343 DOI: 10.3382/ps.2011-01764] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
13 Ghosh S, Tan F, Yu T, Li Y, Adisa O, Mosunjac M, Ofori-Acquah SF. Global gene expression profiling of endothelium exposed to heme reveals an organ-specific induction of cytoprotective enzymes in sickle cell disease. PLoS One 2011;6:e18399. [PMID: 21483798 DOI: 10.1371/journal.pone.0018399] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
14 Gra O, Mityaeva O, Berdichevets I, Kozhekbaeva Z, Fesenko D, Kurbatova O, Goldenkova-pavlova I, Nasedkina T. Microarray-Based Detection of CYP1A1 , CYP2C9 , CYP2C19 , CYP2D6 , GSTT1 , GSTM1 , MTHFR , MTRR , NQO1 , NAT2 , HLA-DQA1 , and AB0 Allele Frequencies in Native Russians. Genetic Testing and Molecular Biomarkers 2010;14:329-42. [DOI: 10.1089/gtmb.2009.0158] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
15 Hertz DL, Rae JM. Pharmacogenetic Predictors of Response. In: Stearns V, editor. Novel Biomarkers in the Continuum of Breast Cancer. Cham: Springer International Publishing; 2016. pp. 191-215. [DOI: 10.1007/978-3-319-22909-6_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
16 Hang H, Wang LK, Ren SY, Song AJ, Wu GF. Activating PPARγ Increases NQO1 and γ-GCS Expression via Nrf2 in Thrombin-activated Microglia. Curr Med Sci 2020;40:55-62. [PMID: 32166665 DOI: 10.1007/s11596-020-2146-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 2011;32:1107-21. [PMID: 21464040 DOI: 10.1093/carcin/bgr066] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
18 Muranen TA, Mavaddat N, Khan S, Fagerholm R, Pelttari L, Lee A, Aittomäki K, Blomqvist C, Easton DF, Nevanlinna H. Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. Breast Cancer Res Treat 2016;158:463-9. [PMID: 27438779 DOI: 10.1007/s10549-016-3897-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
19 Khrunin AV, Khokhrin DV, Moisseev AA, Gorbunova VA, Limborska SA. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics 2014;15:329-37. [PMID: 24533712 DOI: 10.2217/pgs.13.237] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
20 Fuksa L, Micuda S, Grim J, Ryska A, Hornychova H. Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy. Cancer Investigation 2012;30:663-78. [DOI: 10.3109/07357907.2012.725441] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
21 Shu XO, Long J, Lu W, Li C, Chen WY, Delahanty R, Cheng J, Cai H, Zheng Y, Shi J, Gu K, Wang WJ, Kraft P, Gao YT, Cai Q, Zheng W. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res 2012;72:1182-9. [PMID: 22232737 DOI: 10.1158/0008-5472.CAN-11-2561] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
22 Aloraifi F, McDevitt T, Martiniano R, McGreevy J, McLaughlin R, Egan CM, Cody N, Meany M, Kenny E, Green AJ, Bradley DG, Geraghty JG, Bracken AP. Detection of novel germline mutations for breast cancer in non-BRCA1/2 families. FEBS J 2015;282:3424-37. [PMID: 26094658 DOI: 10.1111/febs.13352] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
23 Azzato EM, Pharoah PD, Harrington P, Easton DF, Greenberg D, Caporaso NE, Chanock SJ, Hoover RN, Thomas G, Hunter DJ, Kraft P. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev 2010;19:1140-3. [PMID: 20332263 DOI: 10.1158/1055-9965.EPI-10-0085] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
24 Dai X, Li L, Liu X, Hu W, Yang Y, Bai Z. Cooperation of DLC1 and CDK6 affects breast cancer clinical outcome. G3 (Bethesda) 2014;5:81-91. [PMID: 25425654 DOI: 10.1534/g3.114.014894] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
25 Wu JM, Oraee A, Doonan BB, Pinto JT, Hsieh TC. Activation of NQO1 in NQO1*2 polymorphic human leukemic HL-60 cells by diet-derived sulforaphane. Exp Hematol Oncol 2015;5:27. [PMID: 27625902 DOI: 10.1186/s40164-016-0056-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95-107. [PMID: 19165225 DOI: 10.1038/nrc2584] [Cited by in Crossref: 427] [Cited by in F6Publishing: 394] [Article Influence: 32.8] [Reference Citation Analysis]
27 Zhu W, Deng Y, Jie K, Luo D, Liu Z, Yu L, Zeng E, Wan F. Detection of single nucleotide polymorphisms by PCR conformation-difference gel electrophoresis. Biotechnol Lett 2013;35:515-22. [DOI: 10.1007/s10529-012-1115-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Qian DC, Byun J, Han Y, Greene CS, Field JK, Hung RJ, Brhane Y, Mclaughlin JR, Fehringer G, Landi MT, Rosenberger A, Bickeböller H, Malhotra J, Risch A, Heinrich J, Hunter DJ, Henderson BE, Haiman CA, Schumacher FR, Eeles RA, Easton DF, Seminara D, Amos CI. Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. Hum Mol Genet 2015;24:7406-20. [PMID: 26483192 DOI: 10.1093/hmg/ddv440] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hershkovitz Rokah O, Shpilberg O, Granot G. NAD(P)H quinone oxidoreductase protects TAp63gamma from proteasomal degradation and regulates TAp63gamma-dependent growth arrest. PLoS One 2010;5:e11401. [PMID: 20613985 DOI: 10.1371/journal.pone.0011401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
30 Ryan A. Azoreductases in drug metabolism. Br J Pharmacol. 2017;174:2161-2173. [PMID: 27487252 DOI: 10.1111/bph.13571] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
31 Yao Y, Brodie AM, Davidson NE, Kensler TW, Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat 2010;124:585-91. [PMID: 20623181 DOI: 10.1007/s10549-010-1023-8] [Cited by in F6Publishing: 55] [Reference Citation Analysis]
32 Neven P, Van Gorp T, Deraedt K. A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis. Breast Cancer Res 2008;10:109. [PMID: 18828867 DOI: 10.1186/bcr2135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
33 Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008;2:296-316. [PMID: 19383352 DOI: 10.1016/molonc.2008.09.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 2011;85:241-72. [PMID: 21365312 DOI: 10.1007/s00204-011-0674-5] [Cited by in Crossref: 616] [Cited by in F6Publishing: 595] [Article Influence: 56.0] [Reference Citation Analysis]
35 Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J, Bartek J. DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. Mol Oncol 2016;10:879-94. [PMID: 26987799 DOI: 10.1016/j.molonc.2016.02.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
36 Lee J, Kim KS, Lee MH, Kim YS, Lee MH, Lee SE, Kim YK, Ryu MJ, Kim SJ, Choi MJ, Jo YS. NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype. Yonsei Med J 2013;54:1158-67. [PMID: 23918565 DOI: 10.3349/ymj.2013.54.5.1158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
37 Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EV, Verrill MW, May FE, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet Genomics 2011;21:808-19. [PMID: 21946896 DOI: 10.1097/FPC.0b013e32834b6918] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
38 Jortzik E, Wang L, Ma J, Becker K. Flavins and Flavoproteins: Applications in Medicine. In: Weber S, Schleicher E, editors. Flavins and Flavoproteins. New York: Springer; 2014. pp. 113-57. [DOI: 10.1007/978-1-4939-0452-5_7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
39 Li Y, Tang XQ, Bai Z, Dai X. Exploring the intrinsic differences among breast tumor subtypes defined using immunohistochemistry markers based on the decision tree. Sci Rep 2016;6:35773. [PMID: 27786176 DOI: 10.1038/srep35773] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Dai X, Liu Z, Zhang S. Over-expression of EPS15 is a favorable prognostic factor in breast cancer. Mol Biosyst 2015;11:2978-85. [PMID: 26289382 DOI: 10.1039/c5mb00219b] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
41 Cabello CM, Lamore SD, Bair WB 3rd, Davis AL, Azimian SM, Wondrak GT. DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic Res 2011;45:276-92. [PMID: 21034357 DOI: 10.3109/10715762.2010.526766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
42 Heikkinen T, Greco D, Pelttari LM, Tommiska J, Vahteristo P, Heikkilä P, Blomqvist C, Aittomäki K, Nevanlinna H. Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res 2011;13:R130. [PMID: 22171747 DOI: 10.1186/bcr3076] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
43 Häberle L, Hein A, Rübner M, Schneider M, Ekici AB, Gass P, Hartmann A, Schulz-Wendtland R, Beckmann MW, Lo WY, Schroth W, Brauch H, Fasching PA, Wunderle M. Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. Geburtshilfe Frauenheilkd 2017;77:667-78. [PMID: 28757654 DOI: 10.1055/s-0043-111602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
44 Hemminki K, Sundquist J, Brandt A. Familial mortality and familial incidence in cancer. J Clin Oncol 2011;29:712-8. [PMID: 21205747 DOI: 10.1200/JCO.2010.30.5664] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
45 Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012;83:1033-40. [PMID: 22209713 DOI: 10.1016/j.bcp.2011.12.017] [Cited by in Crossref: 181] [Cited by in F6Publishing: 170] [Article Influence: 16.5] [Reference Citation Analysis]
46 Heikkinen T, Khan S, Huovari E, Vilske S, Schleutker J, Kallioniemi A, Blomqvist C, Aittomäki K, Nevanlinna H. Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. Breast Cancer Res Treat 2014;144:437-41. [PMID: 24562772 DOI: 10.1007/s10549-014-2884-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Agarwal G, Tulsyan S, Lal P, Mittal B. Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients. World J Surg 2016;40:1600-10. [DOI: 10.1007/s00268-015-3263-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
48 Thapa D, Meng P, Bedolla RG, Reddick RL, Kumar AP, Ghosh R. NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res 2014;74:5644-55. [PMID: 25125658 DOI: 10.1158/0008-5472.CAN-14-0562] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
49 Jiang ZN, Ahmed SMU, Wang QC, Shi HF, Tang XW. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival. World J Gastroenterol 2021; 27(22): 3085-3096 [PMID: 34168410 DOI: 10.3748/wjg.v27.i22.3085] [Reference Citation Analysis]
50 Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. GammaH2AX and cancer. Nat Rev Cancer. 2008;8:957-967. [PMID: 19005492 DOI: 10.1038/nrc2523] [Cited by in Crossref: 1057] [Cited by in F6Publishing: 1021] [Article Influence: 75.5] [Reference Citation Analysis]
51 Tentner AR, Lee MJ, Ostheimer GJ, Samson LD, Lauffenburger DA, Yaffe MB. Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol Syst Biol 2012;8:568. [PMID: 22294094 DOI: 10.1038/msb.2012.1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
52 Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK; NBCS Collaborators. Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer 2019;120:647-57. [PMID: 30787463 DOI: 10.1038/s41416-019-0393-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
53 Nagata M, Kimura T, Suzumura T, Kira Y, Nakai T, Umekawa K, Tanaka H, Matsuura K, Mitsuoka S, Yoshimura N, Oka T, Kudoh S, Hirata K. C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. Clin Med Insights Oncol. 2013;7:31-39. [PMID: 23467445 DOI: 10.4137/cmo.s10839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
54 Jamieson D, Boddy AV. Pharmacogenetics of genes across the doxorubicin pathway. Expert Opinion on Drug Metabolism & Toxicology 2011;7:1201-10. [DOI: 10.1517/17425255.2011.610180] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
55 Rafiq S, Khan S, Tapper W, Collins A, Upstill-Goddard R, Gerty S, Blomqvist C, Aittomäki K, Couch FJ, Liu J, Nevanlinna H, Eccles D. A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis. PLoS One 2014;9:e101488. [PMID: 25526632 DOI: 10.1371/journal.pone.0101488] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
56 Li J, Humphreys K, Darabi H, Rosin G, Hannelius U, Heikkinen T, Aittomäki K, Blomqvist C, Pharoah PD, Dunning AM, Ahmed S, Hooning MJ, Hollestelle A, Oldenburg RA, Alfredsson L, Palotie A, Peltonen-Palotie L, Irwanto A, Low HQ, Teoh GH, Thalamuthu A, Kere J, D'Amato M, Easton DF, Nevanlinna H, Liu J, Czene K, Hall P. A genome-wide association scan on estrogen receptor-negative breast cancer. Breast Cancer Res 2010;12:R93. [PMID: 21062454 DOI: 10.1186/bcr2772] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
57 Renaud CO, Ziros PG, Chartoumpekis DV, Bongiovanni M, Sykiotis GP. Keap1/Nrf2 Signaling: A New Player in Thyroid Pathophysiology and Thyroid Cancer. Front Endocrinol (Lausanne) 2019;10:510. [PMID: 31428048 DOI: 10.3389/fendo.2019.00510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
58 Atiomo W, Shafiee MN, Chapman C, Metzler VM, Abouzeid J, Latif A, Chadwick A, Kitson S, Sivalingam VN, Stratford IJ, Rutland CS, Persson JL, Ødum N, Fuentes-Utrilla P, Jeyapalan JN, Heery DM, Crosbie EJ, Mongan NP. Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2017;87:557-65. [PMID: 28748640 DOI: 10.1111/cen.13436] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Bojesen SE, Nordestgaard BG, Flyger H, Milne RL, Arias JI, Menéndez P, Benítez J, Chang-Claude J, Hein R, Wang-Gohrke S, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Margolin S, Mannermaa A, Kosma VM, Kataja V, Beesley J, Chen X, Chenevix-Trench G, Couch FJ, Olson JE, Fredericksen ZS, Wang X, Giles GG, Severi G, Baglietto L, Southey MC, Devilee P, Tollenaar RA, Seynaeve C, García-Closas M, Lissowska J, Sherman ME, Bolton KL, Hall P, Czene K, Cox A, Brock IW, Elliott GC, Reed MW, Greenberg D, Anton-Culver H, Ziogas A, Humphreys M, Easton DF, Caporaso NE, Pharoah PD; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst 2010;102:650-62. [PMID: 20308648 DOI: 10.1093/jnci/djq057] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
60 Guo Q, Schmidt MK, Kraft P, Canisius S, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J, Michailidou K, Lush M, Kar S, Beesley J, Dunning AM, Shah M, Czene K, Darabi H, Eriksson M, Lambrechts D, Weltens C, Leunen K, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Blomqvist C, Aittomäki K, Fagerholm R, Muranen TA, Couch FJ, Olson JE, Vachon C, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Broeks A, Hogervorst FB, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Cox A, Cross SS, Reed MW, Giles GG, Milne RL, McLean C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Hooning MJ, Hollestelle A, Martens JW, van den Ouweland AM, Marme F, Schneeweiss A, Yang R, Burwinkel B, Figueroa J, Chanock SJ, Lissowska J, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Brenner H, Dieffenbach AK, Arndt V, Holleczek B, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Li J, Brand JS, Humphreys K, Devilee P, Tollenaar RA, Seynaeve C, Radice P, Peterlongo P, Bonanni B, Mariani P, Fasching PA, Beckmann MW, Hein A, Ekici AB, Chenevix-Trench G, Balleine R, Phillips KA, Benitez J, Zamora MP, Arias Perez JI, Menéndez P, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Hamann U, Kabisch M, Ulmer HU, Rüdiger T, Margolin S, Kristensen V, Nord S, Evans DG, Abraham JE, Earl HM, Hiller L, Dunn JA, Bowden S, Berg C, Campa D, Diver WR, Gapstur SM, Gaudet MM, Hankinson SE, Hoover RN, Hüsing A, Kaaks R, Machiela MJ, Willett W, Barrdahl M, Canzian F, Chin SF, Caldas C, Hunter DJ, Lindstrom S, García-Closas M, Hall P, Easton DF, Eccles DM, Rahman N, Nevanlinna H, Pharoah PD; kConFab Investigators. Identification of novel genetic markers of breast cancer survival. J Natl Cancer Inst 2015;107:djv081. [PMID: 25890600 DOI: 10.1093/jnci/djv081] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
61 Kiiski JI, Tervasmäki A, Pelttari LM, Khan S, Mantere T, Pylkäs K, Mannermaa A, Tengström M, Kvist A, Borg Å, Kosma VM, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Winqvist R, Nevanlinna H. FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. Breast Cancer Res Treat 2017;166:217-26. [PMID: 28702895 DOI: 10.1007/s10549-017-4388-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
62 Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 2013;24:1513-25. [PMID: 23396606 DOI: 10.1093/annonc/mdt008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
63 Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dörk T. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res. 2009;11:R89. [PMID: 20021639 DOI: 10.1186/bcr2460] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
64 Pirie A, Guo Q, Kraft P, Canisius S, Eccles DM, Rahman N, Nevanlinna H, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J, Michailidou K, Lush M, Dunning AM, Shah M, Czene K, Darabi H, Eriksson M, Lambrechts D, Weltens C, Leunen K, van Ongeval C, Nordestgaard BG, Nielsen SF, Flyger H, Rudolph A, Seibold P, Flesch-Janys D, Blomqvist C, Aittomäki K, Fagerholm R, Muranen TA, Olsen JE, Hallberg E, Vachon C, Knight JA, Glendon G, Mulligan AM, Broeks A, Cornelissen S, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Cross SS, Reed MW, Giles GG, Milne RL, McLean C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Hooning MJ, Hollestelle A, Martens JW, van den Ouweland AM, Marme F, Schneeweiss A, Yang R, Burwinkel B, Figueroa J, Chanock SJ, Lissowska J, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Brenner H, Butterbach K, Holleczek B, Kataja V, Kosma VM, Hartikainen JM, Li J, Brand JS, Humphreys K, Devilee P, Tollenaar RA, Seynaeve C, Radice P, Peterlongo P, Manoukian S, Ficarazzi F, Beckmann MW, Hein A, Ekici AB, Balleine R, Phillips KA, Benitez J, Zamora MP, Perez JI, Menéndez P, Jakubowska A, Lubinski J, Gronwald J, Durda K, Hamann U, Kabisch M, Ulmer HU, Rüdiger T, Margolin S, Kristensen V, Nord S, Evans DG, Abraham J, Earl H, Poole CJ, Hiller L, Dunn JA, Bowden S, Yang R, Campa D, Diver WR, Gapstur SM, Gaudet MM, Hankinson S, Hoover RN, Hüsing A, Kaaks R, Machiela MJ, Willett W, Barrdahl M, Canzian F, Chin SF, Caldas C, Hunter DJ, Lindstrom S, Garcia-Closas M, Couch FJ, Chenevix-Trench G, Mannermaa A, Andrulis IL, Hall P, Chang-Claude J, Easton DF, Bojesen SE, Cox A, Fasching PA, Pharoah PD, Schmidt MK; kConFab Investigators., NBCS Investigators. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Res 2015;17:58. [PMID: 25897948 DOI: 10.1186/s13058-015-0570-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
65 Okubo A, Yasuhira S, Shibazaki M, Takahashi K, Akasaka T, Masuda T, Maesawa C. NAD(P)H dehydrogenase, quinone 1 (NQO1), protects melanin-producing cells from cytotoxicity of rhododendrol. Pigment Cell Melanoma Res 2016;29:309-16. [PMID: 26847926 DOI: 10.1111/pcmr.12461] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
66 Rodrigues P, Furriol J, Bermejo B, Chaves FJ, Lluch A, Eroles P. Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients. Int J Mol Sci 2012;13:16500-13. [PMID: 23443115 DOI: 10.3390/ijms131216500] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Fagerholm R, Khan S, Schmidt MK, García-Closas M, Heikkilä P, Saarela J, Beesley J, Jamshidi M, Aittomäki K, Liu J, Ali HR, Andrulis IL, Beckmann MW, Behrens S, Blows FM, Brenner H, Chang-Claude J, Couch FJ, Czene K, Fasching PA, Figueroa J, Floris G, Glendon G, Guo Q, Hall P, Hallberg E, Hamann U, Holleczek B, Hooning MJ, Hopper JL, Jager A, Kabisch M, Keeman R, Kosma VM, Lambrechts D, Lindblom A, Mannermaa A, Margolin S, Provenzano E, Shah M, Southey MC, Dennis J, Lush M, Michailidou K, Wang Q, Bolla MK, Dunning AM, Easton DF, Pharoah PD, Chenevix-Trench G, Blomqvist C, Nevanlinna H; kConFab/AOCS Investigators. TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget 2017;8:18381-98. [PMID: 28179588 DOI: 10.18632/oncotarget.15110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
68 Muranen TA, Greco D, Fagerholm R, Kilpivaara O, Kämpjärvi K, Aittomäki K, Blomqvist C, Heikkilä P, Borg A, Nevanlinna H. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. Breast Cancer Res 2011;13:R90. [PMID: 21542898 DOI: 10.1186/bcr3015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
69 Paleček E. Fifty Years of Nucleic Acid Electrochemistry. Electroanalysis 2009;21:239-51. [DOI: 10.1002/elan.200804416] [Cited by in Crossref: 76] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
70 Wiechec E, Hansen LL. The effect of genetic variability on drug response in conventional breast cancer treatment. European Journal of Pharmacology 2009;625:122-30. [DOI: 10.1016/j.ejphar.2009.08.045] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
71 Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van't Veer LJ, Udo R, Dunning AM, Greco D, Aittomäki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dörk T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olson JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John EM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G, Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Pérez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK; kConFab Investigators. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012;21:3926-39. [PMID: 22532573 DOI: 10.1093/hmg/dds159] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
72 Kharazmi E, Försti A, Sundquist K, Hemminki K. Survival in familial and non-familial breast cancer by age and stage at diagnosis. Eur J Cancer 2016;52:10-8. [PMID: 26630529 DOI: 10.1016/j.ejca.2015.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
73 Marin JJ, Monte MJ, Blazquez AG, Macias RI, Serrano MA, Briz O. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacol Sin 2014;35:1-10. [PMID: 24317012 DOI: 10.1038/aps.2013.131] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
74 Wendt C, Muranen TA, Mielikäinen L, Thutkawkorapin J, Blomqvist C, Jiao X, Ehrencrona H, Tham E, Arver B, Melin B, Kuchinskaya E, Stenmark Askmalm M, Paulsson-Karlsson Y, Einbeigi Z, von Wachenfeldt Väppling A, Kalso E, Tasmuth T, Kallioniemi A, Aittomäki K, Nevanlinna H, Borg Å, Lindblom A. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. Sci Rep 2021;11:14763. [PMID: 34285278 DOI: 10.1038/s41598-021-93926-x] [Reference Citation Analysis]
75 Kucera HR, Livingstone M, Moscoso CG, Gaikwad NW. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides. Free Radic Res 2013;47:1016-26. [PMID: 24074361 DOI: 10.3109/10715762.2013.847527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
76 Cho MK, Lim CS, Sarkar AR, Lee HW, Choi HJ, Noh C, Shin SJ, Kim HM. A two-photon ratiometric probe for detection of hNQO1 enzyme activity in human colon tissue. Sensors and Actuators B: Chemical 2018;272:203-10. [DOI: 10.1016/j.snb.2018.05.144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
77 Völler S, Boos J, Krischke M, Würthwein G, Kontny NE, Boddy AV, Hempel G. Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. Clin Pharmacokinet 2015;54:1139-49. [DOI: 10.1007/s40262-015-0272-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
78 Das L, Vinayak M. Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer. PLoS One 2015;10:e0124000. [PMID: 25860911 DOI: 10.1371/journal.pone.0124000] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
79 Kiiski JI, Fagerholm R, Tervasmäki A, Pelttari LM, Khan S, Jamshidi M, Mantere T, Pylkäs K, Bartek J, Bartkova J, Mannermaa A, Tengström M, Kosma VM, Winqvist R, Kallioniemi A, Aittomäki K, Blomqvist C, Nevanlinna H. FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. Int J Cancer 2016;139:2760-70. [PMID: 27542569 DOI: 10.1002/ijc.30394] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
80 Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB, Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ, Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN, Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H; kConFab Investigators., HEBON Investigators., SWE-BRCA Investigators. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. NPJ Breast Cancer 2020;6:44. [PMID: 32964118 DOI: 10.1038/s41523-020-00185-6] [Reference Citation Analysis]
81 Fagerholm R, Schmidt MK, Khan S, Rafiq S, Tapper W, Aittomäki K, Greco D, Heikkinen T, Muranen TA, Fasching PA, Janni W, Weinshilboum R, Loehberg CR, Hopper JL, Southey MC, Keeman R, Lindblom A, Margolin S, Mannermaa A, Kataja V, Chenevix-Trench G, Lambrechts D, Wildiers H, Chang-Claude J, Seibold P, Couch FJ, Olson JE, Andrulis IL, Knight JA, García-Closas M, Figueroa J, Hooning MJ, Jager A, Shah M, Perkins BJ, Luben R, Hamann U, Kabisch M, Czene K, Hall P, Easton DF, Pharoah PD, Liu J, Eccles D, Blomqvist C, Nevanlinna H; kConFab Investigators. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget 2015;6:7390-407. [PMID: 25823661 DOI: 10.18632/oncotarget.3506] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
82 Palanca Suela S, Esteban Cardeñosa E, Barragán González E, de Juan Jiménez I, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E, Montalar Salcedo J, Castel Sánchez V, Bolufer Gilabert P; Group for Assessment of Hereditary Cancer of Valencia Community. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. Breast Cancer Res Treat 2010;119:87-93. [PMID: 19214744 DOI: 10.1007/s10549-009-0316-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
83 Szaefer H, Krajka-kuźniak V, Licznerska B, Bartoszek A, Baer-dubowska W. Cabbage Juices and Indoles Modulate the Expression Profile of AhR, ERα, and Nrf2 in Human Breast Cell Lines. Nutrition and Cancer 2015;67:1344-56. [DOI: 10.1080/01635581.2015.1082111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
84 Pelttari LM, Kiiski JI, Ranta S, Vilske S, Blomqvist C, Aittomäki K, Nevanlinna H. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. Springerplus 2015;4:92. [PMID: 25918678 DOI: 10.1186/s40064-015-0880-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
85 Kim HI, Lim H, Moon A. Sex Differences in Cancer: Epidemiology, Genetics and Therapy. Biomol Ther (Seoul) 2018;26:335-42. [PMID: 29949843 DOI: 10.4062/biomolther.2018.103] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 13.5] [Reference Citation Analysis]
86 Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008;2:296-316. [PMID: 19383352 DOI: 10.1016/j.molonc.2008.09.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 7.8] [Reference Citation Analysis]
87 Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, Li D. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 2011;125:467-72. [PMID: 20526805 DOI: 10.1007/s10549-010-0966-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
88 Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010;501:116-23. [PMID: 20361926 DOI: 10.1016/j.abb.2010.03.019] [Cited by in Crossref: 440] [Cited by in F6Publishing: 417] [Article Influence: 36.7] [Reference Citation Analysis]
89 Dai X, Chen A, Bai Z. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Sci Rep 2014;4:6566. [PMID: 25338681 DOI: 10.1038/srep06566] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
90 Hallamies S, Pelttari LM, Poikonen-Saksela P, Jekunen A, Jukkola-Vuorinen A, Auvinen P, Blomqvist C, Aittomäki K, Mattson J, Nevanlinna H. CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. BMC Cancer 2017;17:620. [PMID: 28874143 DOI: 10.1186/s12885-017-3631-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
91 Hubackova M, Vaclavikova R, Ehrlichova M, Mrhalova M, Kodet R, Kubackova K, Vrána D, Gut I, Soucek P. Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer 2012;130:338-48. [PMID: 21351093 DOI: 10.1002/ijc.26006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
92 Jamshidi M, Fagerholm R, Khan S, Aittomäki K, Czene K, Darabi H, Li J, Andrulis IL, Chang-Claude J, Devilee P, Fasching PA, Michailidou K, Bolla MK, Dennis J, Wang Q, Guo Q, Rhenius V, Cornelissen S, Rudolph A, Knight JA, Loehberg CR, Burwinkel B, Marme F, Hopper JL, Southey MC, Bojesen SE, Flyger H, Brenner H, Holleczek B, Margolin S, Mannermaa A, Kosma VM, Van Dyck L, Nevelsteen I, Couch FJ, Olson JE, Giles GG, McLean C, Haiman CA, Henderson BE, Winqvist R, Pylkäs K, Tollenaar RA, García-Closas M, Figueroa J, Hooning MJ, Martens JW, Cox A, Cross SS, Simard J, Dunning AM, Easton DF, Pharoah PD, Hall P, Blomqvist C, Schmidt MK, Nevanlinna H; kConFab Investigators. SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival. Oncotarget 2015;6:37979-94. [PMID: 26317411 DOI: 10.18632/oncotarget.4991] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
93 Rofaiel S, Muo EN, Mousa SA. Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med 2010;3:129-43. [PMID: 23226048 DOI: 10.2147/PGPM.S10789] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, Verrill M, Boddy AV. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol 2014;74:667-74. [PMID: 25055937 DOI: 10.1007/s00280-014-2541-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
95 Fagerholm R, Faltinova M, Aaltonen K, Aittomäki K, Heikkilä P, Halttunen-Nieminen M, Nevanlinna H, Blomqvist C. Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy. Fam Cancer 2018;17:321-31. [PMID: 29019086 DOI: 10.1007/s10689-017-0046-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
96 Low YL, Li Y, Humphreys K, Thalamuthu A, Li Y, Darabi H, Wedrén S, Bonnard C, Czene K, Iles MM, Heikkinen T, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Liu ET, Liu J. Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLoS Genet 2010;6:e1001012. [PMID: 20617168 DOI: 10.1371/journal.pgen.1001012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
97 Kadalayil L, Khan S, Nevanlinna H, Fasching PA, Couch FJ, Hopper JL, Liu J, Maishman T, Durcan L, Gerty S, Blomqvist C, Rack B, Janni W, Collins A, Eccles D, Tapper W. Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. Nat Commun 2017;8:1632. [PMID: 29158497 DOI: 10.1038/s41467-017-01775-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
98 Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 2009;17:722-31. [PMID: 19092773 DOI: 10.1038/ejhg.2008.212] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 8.5] [Reference Citation Analysis]
99 Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17:275-85. [PMID: 21224367 DOI: 10.1158/1078-0432.CCR-10-1983] [Cited by in Crossref: 83] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
100 Strandback E, Lienhart WD, Hromic-Jahjefendic A, Bourgeois B, Högler A, Waltenstorfer D, Winkler A, Zangger K, Madl T, Gruber K, Macheroux P. A small molecule chaperone rescues the stability and activity of a cancer-associated variant of NAD(P)H:quinone oxidoreductase 1 in vitro. FEBS Lett 2020;594:424-38. [PMID: 31605637 DOI: 10.1002/1873-3468.13636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
101 Martínez-Magaña JJ, Genis-Mendoza AD, Villatoro Velázquez JA, Camarena B, Martín Del Campo Sanchez R, Fleiz Bautista C, Bustos Gamiño M, Reséndiz E, Aguilar A, Medina-Mora ME, Nicolini H. The Identification of Admixture Patterns Could Refine Pharmacogenetic Counseling: Analysis of a Population-Based Sample in Mexico. Front Pharmacol 2020;11:324. [PMID: 32390825 DOI: 10.3389/fphar.2020.00324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Meindl A. Identification of Novel Susceptibility Genes for Breast Cancer - Genome-Wide Association Studies or Evaluation of Candidate Genes? Breast Care (Basel) 2009;4:93-9. [PMID: 21049069 DOI: 10.1159/000211991] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
103 Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Nevanlinna H. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. Int J Cancer 2019;145:2692-700. [PMID: 30927251 DOI: 10.1002/ijc.32309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
104 Li Z, Zhang Y, Jin T, Men J, Lin Z, Qi P, Piao Y, Yan G. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer. 2015;15:207. [PMID: 25880877 DOI: 10.1186/s12885-015-1227-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
105 Eccles D, Tapper W. The influence of common polymorphisms on breast cancer. Cancer Treat Res 2010;155:15-32. [PMID: 20517686 DOI: 10.1007/978-1-4419-6033-7_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
106 Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomäki K, Mattson J, Villman K, Vrtel R, Lukas J, Heikkilä P, Blomqvist C, Bartek J, Nevanlinna H. NQO1 expression correlates inversely with NFκB activation in human breast cancer. Breast Cancer Res Treat 2012;132:955-68. [DOI: 10.1007/s10549-011-1629-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
107 Hu L, Miao W, Loignon M, Kandouz M, Batist G. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemother Pharmacol 2010;66:467-74. [PMID: 19940992 DOI: 10.1007/s00280-009-1182-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
108 Marsh S, Liu G. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Advanced Drug Delivery Reviews 2009;61:381-7. [DOI: 10.1016/j.addr.2008.10.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
109 Lienhart WD, Gudipati V, Uhl MK, Binter A, Pulido SA, Saf R, Zangger K, Gruber K, Macheroux P. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.). FEBS J 2014;281:4691-704. [PMID: 25143260 DOI: 10.1111/febs.12975] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
110 Mantere T, Tervasmäki A, Nurmi A, Rapakko K, Kauppila S, Tang J, Schleutker J, Kallioniemi A, Hartikainen JM, Mannermaa A, Nieminen P, Hanhisalo R, Lehto S, Suvanto M, Grip M, Jukkola-Vuorinen A, Tengström M, Auvinen P, Kvist A, Borg Å, Blomqvist C, Aittomäki K, Greenberg RA, Winqvist R, Nevanlinna H, Pylkäs K. Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. Sci Rep 2017;7:681. [PMID: 28386063 DOI: 10.1038/s41598-017-00766-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
111 Hubackova M, Vaclavikova R, Mrhalova M, Kubackova K, Kodet R, Gut I, Soucek P. NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristcs of human mammary tumors. Pharmacogenetics and Genomics 2009;19:505-12. [DOI: 10.1097/fpc.0b013e32832cf9cf] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
112 Bartek J Jr, Fornara O, Merchut-Maya JM, Maya-Mendoza A, Rahbar A, Stragliotto G, Broholm H, Svensson M, Sehested A, Söderberg Naucler C, Bartek J, Bartkova J. Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas. Mol Oncol 2017;11:945-64. [PMID: 28383788 DOI: 10.1002/1878-0261.12061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
113 Rajagopal T, Seshachalam A, Rathnam KK, Jothi A, Talluri S, Venkatabalasubramanian S, Dunna NR. Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women. Breast Cancer Res Treat 2021;186:823-37. [PMID: 33392841 DOI: 10.1007/s10549-020-06028-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
114 Tapper W, Hammond V, Gerty S, Ennis S, Simmonds P, Collins A, Eccles D; Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) Steering Group. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 2008;10:R108. [PMID: 19094228 DOI: 10.1186/bcr2213] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
115 Revollo J, Petibone DM, McKinzie P, Knox B, Morris SM, Ning B, Dobrovolsky VN. Whole genome and normalized mRNA sequencing reveal genetic status of TK6, WTK1, and NH32 human B-lymphoblastoid cell lines. Mutat Res Genet Toxicol Environ Mutagen 2016;795:60-9. [PMID: 26774668 DOI: 10.1016/j.mrgentox.2015.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
116 Dai X, Li Y, Bai Z, Tang XQ. Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers. Sci Rep 2015;5:14499. [PMID: 26404658 DOI: 10.1038/srep14499] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
117 Røe OD, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, Erlandsen SE, Dobra K, Sundstrøm SH. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma. PLoS One 2012;7:e40521. [PMID: 22905093 DOI: 10.1371/journal.pone.0040521] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
118 Kang SW, Lee S, Lee EK. ROS and energy metabolism in cancer cells: alliance for fast growth. Arch Pharm Res 2015;38:338-45. [PMID: 25599615 DOI: 10.1007/s12272-015-0550-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 8.1] [Reference Citation Analysis]
119 Paleček E, Bartošík M. Electrochemistry of Nucleic Acids. Chem Rev 2012;112:3427-81. [DOI: 10.1021/cr200303p] [Cited by in Crossref: 486] [Cited by in F6Publishing: 395] [Article Influence: 48.6] [Reference Citation Analysis]
120 Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy? Breast 2013;22:817-23. [PMID: 23489758 DOI: 10.1016/j.breast.2013.02.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
121 Rafiq S, Tapper W, Collins A, Khan S, Politopoulos I, Gerty S, Blomqvist C, Couch FJ, Nevanlinna H, Liu J, Eccles D. Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. Cancer Res 2013;73:1883-91. [PMID: 23319801 DOI: 10.1158/0008-5472.CAN-12-3377] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
122 Liu F, Yu G, Wang G, Liu H, Wu X, Wang Q, Liu M, Liao K, Wu M, Cheng X, Hao H. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer. PLoS One 2012;7:e42138. [PMID: 22848731 DOI: 10.1371/journal.pone.0042138] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
123 Sharifi N. Commentary: Antioxidants for cancer: new tricks for an old dog? Oncologist 2009;14:213-5. [PMID: 19264825 DOI: 10.1634/theoncologist.2008-0219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
124 Carron J, Brito AB, Torelli AC, Oliveira C, Derchain SF, Lima CS, Lourenço GJ. Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer. Med Oncol 2016;33:112. [PMID: 27586145 DOI: 10.1007/s12032-016-0819-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
125 Akhtari FS, Green AJ, Small GW, Havener TM, House JS, Roell KR, Reif DM, McLeod HL, Wiltshire T, Motsinger-Reif AA. High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. PLoS Genet 2021;17:e1009732. [PMID: 34437536 DOI: 10.1371/journal.pgen.1009732] [Reference Citation Analysis]
126 Pierce BL, Ahsan H. Case-only genome-wide interaction study of disease risk, prognosis and treatment. Genet Epidemiol 2010;34:7-15. [PMID: 19434715 DOI: 10.1002/gepi.20427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
127 Ribelles N, Santonja A, Pajares B, Llácer C, Alba E. The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. Cancer Treat Rev 2014;40:293-9. [PMID: 24112814 DOI: 10.1016/j.ctrv.2013.09.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
128 Verkooijen HM, Hartman M, Usel M, Benhamou S, Neyroud-caspar I, Czene K, Vlastos G, Chappuis PO, Bouchardy C, Rapiti E. Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. Int J Cancer 2012;130:2103-10. [DOI: 10.1002/ijc.26206] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
129 Vymetalkova V, Soucek P, Kunicka T, Jiraskova K, Brynychova V, Pardini B, Novosadova V, Polivkova Z, Kubackova K, Kozevnikovova R, Ambrus M, Vodickova L, Naccarati A, Vodicka P. Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes. PLoS One 2015;10:e0134463. [PMID: 26226484 DOI: 10.1371/journal.pone.0134463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
130 Madajewski B, Boatman MA, Chakrabarti G, Boothman DA, Bey EA. Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. Mol Cancer Res 2016;14:14-25. [PMID: 26553038 DOI: 10.1158/1541-7786.MCR-15-0207-T] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
131 Chaturvedi P, Tulsyan S, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B. Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients. Biochem Genet 2015;53:211-22. [PMID: 26014925 DOI: 10.1007/s10528-015-9683-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
132 Adam V, Petrlova J, Wang J, Eckschlager T, Trnkova L, Kizek R. Zeptomole electrochemical detection of metallothioneins. PLoS One 2010;5:e11441. [PMID: 20625429 DOI: 10.1371/journal.pone.0011441] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
133 Li Y, Li Y, Wedrén S, Li G, Charn TH, Desai KV, Bonnard C, Czene K, Humphreys K, Darabi H, Einarsdóttir K, Heikkinen T, Aittomäki K, Blomqvist C, Chia KS, Nevanlinna H, Hall P, Liu ET, Liu J. Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Res 2011;13:R10. [PMID: 21269472 DOI: 10.1186/bcr2817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
134 Jamroziak K, Robak T. Inheritance and clinical outcome in childhood acute lymphoblastic leukemia. Leuk Res 2009;33:889-90. [PMID: 19243820 DOI: 10.1016/j.leukres.2009.01.028] [Reference Citation Analysis]
135 Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ 2010;17:103-8. [DOI: 10.1038/cdd.2009.67] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 7.0] [Reference Citation Analysis]
136 Yu KD, Di GH, Yuan WT, Fan L, Wu J, Hu Z, Shen ZZ, Zheng Y, Huang W, Shao ZM. Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet 2009;18:2502-17. [PMID: 19351655 DOI: 10.1093/hmg/ddp171] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
137 Tabarés-seisdedos R, Rubenstein JLR. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry 2009;14:563-89. [DOI: 10.1038/mp.2009.2] [Cited by in Crossref: 155] [Cited by in F6Publishing: 139] [Article Influence: 11.9] [Reference Citation Analysis]
138 Benavides MA, Hu D, Baraoidan MK, Bruno A, Du P, Lin S, Yang W, Bland KI, Grizzle WE, Bosland MC. L-methionine-induced alterations in molecular signatures in MCF-7 and LNCaP cancer cells. J Cancer Res Clin Oncol 2011;137:441-53. [PMID: 20454975 DOI: 10.1007/s00432-010-0897-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
139 Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Peeters M, van Dam P, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Res Treat 2014;147:557-70. [PMID: 25168315 DOI: 10.1007/s10549-014-3105-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
140 Sampath V, Garland JS, Helbling D, Dimmock D, Mulrooney NP, Simpson PM, Murray JC, Dagle JM. Antioxidant response genes sequence variants and BPD susceptibility in VLBW infants. Pediatr Res 2015;77:477-83. [PMID: 25518008 DOI: 10.1038/pr.2014.200] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
141 Moudra A, Minarik L, Vancurova M, Bartek J, Hodny Z, Jonasova A. NQO1*2 polymorphism predicts overall survival in MDS patients. Br J Haematol 2019;184:305-8. [PMID: 29363755 DOI: 10.1111/bjh.15088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
142 Cabello CM, Bair WB 3rd, Bause AS, Wondrak GT. Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1. Biochem Pharmacol 2009;78:344-54. [PMID: 19394313 DOI: 10.1016/j.bcp.2009.04.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
143 Szkandera J, Absenger G, Dandachi N, Regitnig P, Lax S, Stotz M, Samonigg H, Renner W, Gerger A. Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Mol Genet Genomics 2012;287:755-64. [PMID: 22903472 DOI: 10.1007/s00438-012-0715-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]